tiprankstipranks
Trending News
More News >

InspireMD Launches CGuard Prime Stent in U.S. Market

Story Highlights
  • InspireMD launched the CGuard Prime Carotid Stent System in the U.S. on July 9, 2025.
  • The launch strengthens InspireMD’s U.S. market position with advanced embolic protection technology.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
InspireMD Launches CGuard Prime Stent in U.S. Market

Don’t Miss TipRanks’ Half-Year Sale

InspireMD ( (NSPR) ) has provided an update.

On July 9, 2025, InspireMD announced the U.S. commercial launch of its CGuard® Prime Carotid Stent System, following FDA premarket application approval. This launch represents a significant milestone for InspireMD, which has already captured a double-digit market share in over 30 countries. The CGuard Prime is designed to enhance embolic protection and improve patient safety in stroke prevention, featuring a dual-layer design and SmartFit™ technology. The launch is expected to strengthen InspireMD’s position in the U.S. market, supported by a seasoned commercial team and robust operational infrastructure.

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

Spark’s Take on NSPR Stock

According to Spark, TipRanks’ AI Analyst, NSPR is a Neutral.

InspireMD’s overall score is moderate due to significant financial challenges, including ongoing losses and negative cash flows. Technical analysis indicates bearish trends, and while recent corporate events are positive and the earnings call shows potential, the current financial and technical weaknesses weigh heavily on the score.

To see Spark’s full report on NSPR stock, click here.

More about InspireMD

InspireMD, Inc. operates in the medical device industry, focusing on the development of innovative carotid stent systems. The company aims to set industry standards with its proprietary MicroNet mesh technology, which is designed to offer superior acute results and long-term stroke prevention. InspireMD’s stock is listed on Nasdaq under the ticker symbol NSPR.

Average Trading Volume: 151,214

Technical Sentiment Signal: Sell

Current Market Cap: $68.01M

For a thorough assessment of NSPR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1